6. The composition of claim 5, wherein said second anti-influenza A antibody is an anti-M2e antibody or an anti-HA antibody.

7. A method for the treatment or prevention of an influenza virus infection in a subject, comprising administering to the subject the composition of any one of claims 1-3.

8. The method of claim 7, wherein said anti-M2e antibody is administered at a dosage of between 10 and 40 mg/kg/day.

9. The method of claim 8, wherein said anti-M2e antibody is administered once or twice per day.

10. The method of claim 7, wherein said oseltamivir composition is administered at a dosage of 10 mg/kg.

11. The method of claim 10, wherein said oseltamivir composition is administered once or twice per day.

12. The method of claim 7, wherein said anti-M2e antibody or said oseltamivir composition is administered prior to influenza infection.

13. The method of claim 7, wherein said anti-M2e antibody or said oseltamivir composition is administered after influenza infection.

14. The method of claim 13, wherein said anti-M2e antibody is administered within 4 days or 48 hours after influenza infection.

15. The method of claim 7, wherein said anti-M2e antibody and said oseltamivir composition are administered simultaneously or sequentially.

16. The method of claim 15, wherein said anti-M2e antibody and said oseltamivir composition are administered sequentially, and wherein said anti-M2e antibody is administered before said oseltamivir composition.

17. The method of claim 15, wherein said anti-M2e antibody and said oseltamivir composition are administered sequentially, and wherein said anti-M2e antibody is administered after said oseltamivir composition.

18. A kit comprising the composition of claim 3.

6. The composition of claim 5, wherein said second anti-influenza A antibody is an anti-M2e antibody or an anti-HA antibody.

7. The composition of any one of claims 1-3 for use in the treatment or prevention of an influenza virus infection in a subject.

8. The composition of claim 7, wherein said anti-M2e antibody in the composition is formulated for use at a dosage of between 10 and 40 mg/kg/day.

9. The composition of claim 8, wherein said anti-M2e antibody in the composition is formulated for use once or twice per day.

10. The composition of claim 7, wherein said oseltamivir composition in the composition is formulated for use at a dosage of 10 mg/kg.

11. The composition of claim 10, wherein said oseltamivir composition in the composition is formulated for use once or twice per day.

12. The composition of claim 7, wherein said anti-M2e antibody or said oseltamivir composition in the composition is formulated for use prior to influenza infection.

13. The composition of claim 7, wherein said anti-M2e antibody or said oseltamivir composition in the composition is formulated for use after influenza infection.

14. The composition of claim 13, wherein said anti-M2e antibody in the composition is formulated for use within 4 days or 48 hours after influenza infection.

15. The composition of claim 7, wherein said composition is formulated such that said anti-M2e antibody and said oseltamivir composition are administrable either simultaneously or sequentially.

16. The composition of claim 15, wherein said composition is formulated such that said anti-M2e antibody and said oseltamivir composition are administrable sequentially, and wherein said anti-M2e antibody is administrable before said oseltamivir composition.

17. The composition of claim 15, wherein said composition is formulated such that said anti-M2e antibody and said oseltamivir composition are administrable sequentially, and wherein said anti-M2e antibody is administrable after said oseltamivir composition.

18. Use of the composition of any one of claims 1-3 in the manufacture of a medicament for the treatment or prevention of an influenza virus infection in a subject.

19. The use of claim 18, wherein said anti-M2e antibody in the medicament is formulated for use at a dosage of between 10 and 40 mg/kg/day.

20. The use of claim 19, wherein said anti-M2e antibody in the medicament is formulated for use once or twice per day.

21. The use of claim 18, wherein said oseltamivir composition in the medicament is formulated for use at a dosage of 10 mg/kg.

22. The use of claim 21, wherein said oseltamivir composition in the medicament is formulated for use once or twice per day.

23. The use of claim 18, wherein said anti-M2e antibody or said oseltamivir composition in the medicament is formulated for use prior to influenza infection.

24. The use of claim 18, wherein said anti-M2e antibody or said oseltamivir composition in the medicament is formulated for use after influenza infection.

25. The use of claim 24, wherein said anti-M2e antibody in the medicament is formulated for use within 4 days or 48 hours after influenza infection.

26. The use of claim 18, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used simultaneously or sequentially.

27. The use of claim 26, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used sequentially, and wherein said anti-M2e antibody is used before said oseltamivir composition.

28. The use of claim 26, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used sequentially, and wherein said anti-M2e antibody is used after said oseltamivir composition.

29. A kit comprising the composition of claim 3.